News Room

Shanghai FTZ Fund invests in Zhangjiang Science City based Lyvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics

2021-02-24

Recently, Shanghai FTZ Fund has invested in Lyvgen, a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.